Old Web
English
Sign In
Acemap
>
authorDetail
>
Dolca Thomas
Dolca Thomas
Pfizer
Medicine
Pharmacology
Rituximab
Rheumatoid arthritis
Adverse effect
5
Papers
117
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
2016
British Journal of Clinical Pharmacology
Stanley N. Cohen
Paul Emery
Maria Greenwald
Donghua Yin
Jean‐Claude Becker
L.A. Melia
Ruifeng Li
Barry Gumbiner
Dolca Thomas
George Spencer‐Green
Xu Meng
Show All
Source
Cite
Save
Citations (39)
Clinical considerations for the development of biosimilars in oncology
2015
mAbs
Mark A. Socinski
Giuseppe Curigliano
Ira Jacobs
Barry Gumbiner
Judith MacDonald
Dolca Thomas
Show All
Source
Cite
Save
Citations (40)
SAT0190 A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Patients with Active Rheumatoid Arthritis
2015
Annals of the Rheumatic Diseases
Ira Jacobs
D. Yin
L.A. Melia
Barry Gumbiner
M. Suster
Dolca Thomas
Xu Meng
Show All
Source
Cite
Save
Citations (2)
Development of biosimilars in an era of oncologic drug shortages
2015
Drug Design Development and Therapy
Edward C. Li
Janakiraman Subramanian
Scott Anderson
Dolca Thomas
Jason Mckinley
Ira Jacobs
Show All
Source
Cite
Save
Citations (32)
FRI0309 A Phase I Pharmacokinetics TRIAL Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis with Active Disease in TNF Failures (Reflections B328-01)
2014
Annals of the Rheumatic Diseases
D. Yin
Jean‐Claude Becker
L.A. Melia
Ruifeng Li
Barry Gumbiner
Dolca Thomas
George Spencer‐Green
Xu Meng
Show All
Source
Cite
Save
Citations (4)
1